Phase 2 study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2α (HIF-2α) inhibitor, for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC).

Srinivasan, Ramaprasad, Donskov, Frede, Iliopoulos, Othon · Journal of Clinical Oncology · 2021